{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:08:44Z","timestamp":1792696124344,"version":"4.5.0"},"reference-count":117,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV), a negative-sense single-stranded RNA virus of the Pneumoviridae family, represents the most important pathogen of lower respiratory tract infections in young infants causing yearly epidemics. RSV is also an important respiratory viral pathogen for older subjects, which is second only to seasonal influenza virus infections. RSV represents a substantial public health burden with respect to morbidity and mortality, particularly in developing countries. Prevention and treatment options would therefore lessen the global disease burden. A formalin-inactivated RSV vaccine in the 1960s induced an enhanced disease upon exposure to natural RSV. After this tragical vaccine failure, it took nearly five decades of intensive research before prevention tools were approved by health authorities. The lead was taken by passive immunity approaches with injected monoclonal antibodies directed against the fusion protein F of RSV. The elucidation of the three-dimensional structure of the F protein revealed pre- and postfusion conformations. Subsequently, structure-based antigen engineering of the F protein paved the way for development of a prophylactic vaccine. In 2023, RSV vaccines were approved for maternal vaccination to protect young infants by placental transfer of antibodies and for vaccination in older subjects. Antiviral drugs that target the RSV fusion process, the RSV replicase, or the cytoplasmic viral factories are in development. Important research papers leading to these developments are reviewed here.<\/jats:p>","DOI":"10.1093\/femsml\/uqaf003","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:13:21Z","timestamp":1739114001000},"source":"Crossref","is-referenced-by-count":11,"title":["Respiratory syncytial virus: health burden, disease prevention, and treatment\u2014recent progress and lessons learned"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-8583","authenticated-orcid":false,"given":"Harald","family":"Br\u00fcssow","sequence":"first","affiliation":[{"name":"Laboratory of Gene Technology , Department of Biosystems, KU Leuven, 3001 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2025070306220370900_bib1","doi-asserted-by":"publisher","first-page":"102089","DOI":"10.1016\/j.eclinm.2023.102089","article-title":"Why has the epidemiology of RSV changed during the COVID-19 pandemic?","volume":"61","author":"Abu-Raya","year":"2023","journal-title":"Eclinicalmedicine"},{"key":"2025070306220370900_bib2","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/infdis\/jix031","article-title":"Interference between respiratory syncytial virus and human rhinovirus infection in infancy","volume":"215","author":"Achten","year":"2017","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief history and characterization of enhanced respiratory syncytial virus disease","volume":"23","author":"Acosta","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"2025070306220370900_bib4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1056\/NEJMc2216153","article-title":"Viral lineages in the 2022 RSV surge in the United States","volume":"388","author":"Adams","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMoa2108903","article-title":"EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge","volume":"386","author":"Ahmad","year":"2022","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib6","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1093\/infdis\/jiae205","article-title":"Genomic analysis and surveillance of respiratory syncytial virus (RSV) using wastewater-based epidemiology (WBE)","volume":"230","author":"Allen","year":"2024","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1056\/NEJMoa2314885","article-title":"Nirsevimab and hospitalization for RSV bronchiolitis","volume":"391","author":"Assad","year":"2024","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib9","doi-asserted-by":"publisher","first-page":"25806","DOI":"10.1038\/srep25806","article-title":"Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication","volume":"6","author":"Bailly","year":"2016","journal-title":"Sci Rep"},{"key":"2025070306220370900_bib10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(22)00525-4","article-title":"Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study","volume":"23","author":"Bardsley","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/infdis\/jiad024","article-title":"Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial","volume":"228","author":"Bebia","year":"2023","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1473-3099(22)00544-8","article-title":"Quantifying the RSV immunity debt following COVID-19: a public health matter","volume":"23","author":"Billard","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/infdis\/163.3.679a","article-title":"Age-related prevalence of serum antibody to respiratory syncytial virus in Ecuadorian and German children","volume":"163","author":"Br\u00fcssow","year":"1991","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib14","doi-asserted-by":"publisher","first-page":"e14510","DOI":"10.1111\/1751-7915.14510","article-title":"The antibiotic resistance crisis and the development of new antibiotics","volume":"17","author":"Br\u00fcssow","year":"2024","journal-title":"Microb Biotechnol"},{"key":"2025070306220370900_bib15","first-page":"267","article-title":"Respiratory syncytical virus and metapneumovirus","volume-title":"Field's Virology. Vol 3: RNA Viruses","author":"Buchholz","year":"2023"},{"key":"2025070306220370900_bib16","doi-asserted-by":"publisher","first-page":"e2023061803","DOI":"10.1542\/peds.2023-061803","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"152","author":"Caserta","year":"2023","journal-title":"Pediatrics"},{"key":"2025070306220370900_bib17","doi-asserted-by":"publisher","first-page":"eade0424","DOI":"10.1126\/scitranslmed.ade0424","article-title":"A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine","volume":"14","author":"Chang","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025070306220370900_bib18","doi-asserted-by":"publisher","first-page":"eade6422","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025070306220370900_bib19","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/cid\/ciz1166","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib20","doi-asserted-by":"publisher","first-page":"e13100","DOI":"10.1111\/irv.13100","article-title":"Systematic literature review of the signs and symptoms of respiratory syncytial virus","volume":"17","author":"Colosia","year":"2023","journal-title":"Influenza Resp Viruses"},{"key":"2025070306220370900_bib21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1473-3099(23)00630-8","article-title":"Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis","volume":"24","author":"Cong","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib22","doi-asserted-by":"publisher","first-page":"16761","DOI":"10.1074\/jbc.RA118.004862","article-title":"Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex","volume":"293","author":"Cox","year":"2018","journal-title":"J Biol Chem"},{"key":"2025070306220370900_bib23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"2025070306220370900_bib24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","article-title":"Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Cunningham","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025070306220370900_bib25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/apa.17199","article-title":"A comparative analysis of non-pharmaceutical interventions for preventing the respiratory syncytial virus in 30 European countries","volume":"113","author":"Dallagiacoma","year":"2024","journal-title":"Acta Paediatr"},{"key":"2025070306220370900_bib26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"2025070306220370900_bib27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1473-3099(22)00763-0","article-title":"Decline of RSV-specific antibodies during the COVID-19 pandemic","volume":"23","author":"den\u00a0Hartog","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib28","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib30","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion F protein-based maternal vaccine\u2014preterm birth and other outcomes","volume":"390","author":"Dieussaert","year":"2024","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1056\/NEJMc2112186","article-title":"Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity","volume":"386","author":"Domachowske","year":"2022","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib32","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib35","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1473-3099(24)00226-3","article-title":"Long-term efficacy and immunogenicity of Ad26.RSV.PreF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study","volume":"24","author":"Falsey","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib38","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and safety of an Ad26.RSV.PreF-RSV preF protein vaccine in older adults","volume":"388","author":"Falsey","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib39","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1016\/S1473-3099(23)00568-6","article-title":"The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness","volume":"24","author":"Feikin","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/cid\/ciad471","article-title":"Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions","volume":"78","author":"Feldman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib41","doi-asserted-by":"publisher","first-page":"e2829","DOI":"10.1093\/cid\/ciaa1906","article-title":"The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures","volume":"73","author":"Foley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib42","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00570-X","article-title":"Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study","author":"Fourati","year":"2024,","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jcv.2010.05.007","article-title":"Correlation of viral load of respiratory pathogens and co-infections with disease severity in children hospitalized for lower respiratory tract infection","volume":"48","author":"Franz","year":"2010","journal-title":"J Clin Virol"},{"key":"2025070306220370900_bib44","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/S1473-3099(22)00510-2","article-title":"Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the Global Burden of Disease Study 2019","volume":"22","author":"GBD 2019 LRI Collaborators","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib46","doi-asserted-by":"publisher","first-page":"e1107","DOI":"10.1055\/a-1990-2633","article-title":"Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: a systematic review","volume":"41","author":"Gonzales","year":"2024","journal-title":"Am J Perinatol"},{"key":"2025070306220370900_bib47","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","author":"Goswami","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib49","doi-asserted-by":"publisher","first-page":"126234","DOI":"10.1016\/j.vaccine.2024.126234","article-title":"Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina","volume":"42","author":"Gui\u00f1az\u00fa","year":"2024","journal-title":"Vaccine"},{"key":"2025070306220370900_bib50","doi-asserted-by":"publisher","first-page":"e4384","DOI":"10.1093\/cid\/ciaa1612","article-title":"Respiratory syncytial virus disease severity in young children","volume":"73","author":"Haddadin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib51","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib52","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib53","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41564-022-01242-5","article-title":"Coinfection by influenza A virus and respiratory syncytial virus produces hybrid virus particles","volume":"7","author":"Haney","year":"2022","journal-title":"Nat Microbiol"},{"key":"2025070306220370900_bib54","doi-asserted-by":"publisher","first-page":"e220527","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025070306220370900_bib55","doi-asserted-by":"publisher","first-page":"e13176","DOI":"10.1111\/irv.13176","article-title":"Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: a phase 2 proof-of-concept trial","volume":"17","author":"Huang","year":"2023","journal-title":"Influenza Resp Viruses"},{"key":"2025070306220370900_bib56","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons","volume":"78","author":"Ison","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib57","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib58","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am J Epidemiol"},{"key":"2025070306220370900_bib59","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"2025070306220370900_bib60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12916-023-02806-w","article-title":"Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa","volume":"21","author":"Koltai","year":"2023","journal-title":"BMC Med"},{"key":"2025070306220370900_bib61","doi-asserted-by":"publisher","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat Commun"},{"key":"2025070306220370900_bib62","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/cid\/cit471","article-title":"High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections","volume":"57","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib63","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/infdis\/jiac327","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1\/2 randomized clinical trial","volume":"227","author":"Leroux-Roels","year":"2023","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12916-020-01537-6","article-title":"Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries","volume":"18","author":"Li","year":"2020","journal-title":"BMC Med"},{"key":"2025070306220370900_bib65","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"2025070306220370900_bib66","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/j.1469-0691.2010.03304.x","article-title":"Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis","volume":"17","author":"Luo","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2025070306220370900_bib67","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12916-023-02827-5","article-title":"Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries","volume":"21","author":"Mahmud","year":"2023","journal-title":"BMC Med"},{"key":"2025070306220370900_bib69","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/cid\/ciz1167","article-title":"A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract","volume":"71","author":"Marty","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib70","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0140-6736(24)01716-1","article-title":"Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies","volume":"404","author":"Mazur","year":"2024","journal-title":"Lancet"},{"key":"2025070306220370900_bib71","doi-asserted-by":"publisher","first-page":"ofac300","DOI":"10.1093\/ofid\/ofac300","article-title":"Rates of medically attended RSV among US adults: a systematic review and meta-analysis","volume":"9","author":"McLaughlin","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025070306220370900_bib72","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2025070306220370900_bib73","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2025070306220370900_bib74","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1413456","article-title":"Viral bronchiolitis in children","volume":"374","author":"Meissner","year":"2016","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib75","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(22)01277-6","article-title":"Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption","volume":"400","author":"Messacar","year":"2022","journal-title":"Lancet"},{"key":"2025070306220370900_bib76","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nm1456","article-title":"A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines","volume":"12","author":"Moghaddam","year":"2006","journal-title":"Nat Med"},{"key":"2025070306220370900_bib77","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants","volume":"388","author":"Muller","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib78","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/infdis\/jiz390","article-title":"Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants","volume":"220","author":"Mu\u0148oz","year":"2019","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib79","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1017\/S0950268816000339","article-title":"Extensive multiplex PCR diagnostics reveal new insights into the epidemiology of viral respiratory infections","volume":"144","author":"Nickbakhsh","year":"2016","journal-title":"Epidemiol Infect"},{"key":"2025070306220370900_bib80","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2352-4642(22)00371-6","article-title":"Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study","volume":"7","author":"Nygaard","year":"2023","journal-title":"Lancet Child & Adolesc Health"},{"key":"2025070306220370900_bib81","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.4049\/jimmunol.179.8.5415","article-title":"CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"179","author":"Olson","year":"2007","journal-title":"J Immunol"},{"key":"2025070306220370900_bib82","doi-asserted-by":"publisher","first-page":"E172","DOI":"10.15167\/2421-4248\/jpmh2024.65.2.3329","article-title":"First real-world data on universal respiratory syncytial virus prophylaxis with nirsevimab in infants","volume":"65","author":"Orsi","year":"2024","journal-title":"J Prev Med Hyg"},{"key":"2025070306220370900_bib83","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib84","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet"},{"key":"2025070306220370900_bib85","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(24)01699-4","article-title":"Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children","volume":"404","author":"Pecenka","year":"2024","journal-title":"Lancet"},{"key":"2025070306220370900_bib86","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3201\/eid2802.211727","article-title":"Viral interference between respiratory viruses","volume":"28","author":"Piret","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025070306220370900_bib87","doi-asserted-by":"publisher","first-page":"eabj7843","DOI":"10.1126\/scitranslmed.abj7843","article-title":"Fatal enhanced respiratory syncytial virus disease in toddlers","volume":"13","author":"Polack","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025070306220370900_bib88","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"key":"2025070306220370900_bib89","doi-asserted-by":"publisher","first-page":"e02312","DOI":"10.1128\/AAC.02312-19","article-title":"Assessment of drug resistance during phase 2b clinical trials of presatovir in adults naturally infected with respiratory syncytial virus","volume":"64","author":"Porter","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070306220370900_bib90","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1016\/j.vaccine.2014.09.030","article-title":"An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization","volume":"32","author":"Raghunandan","year":"2014","journal-title":"Vaccine"},{"key":"2025070306220370900_bib91","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1093\/infdis\/jiac192","article-title":"Waning immunity against respiratory syncytial virus during the coronavirus disease 2019 pandemic","volume":"226","author":"Reicherz","year":"2022","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib92","doi-asserted-by":"publisher","first-page":"e1009428","DOI":"10.1371\/journal.ppat.1009428","article-title":"EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model","volume":"17","author":"Rhodin","year":"2021","journal-title":"PLoS Pathog"},{"key":"2025070306220370900_bib93","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41586-021-03703-z","article-title":"A condensate-hardening drug blocks RSV replication in vivo","volume":"595","author":"Risso-Ballester","year":"2021","journal-title":"Nature"},{"key":"2025070306220370900_bib94","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: from mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"2025070306220370900_bib95","doi-asserted-by":"publisher","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60\u2009years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Resp Viruses"},{"key":"2025070306220370900_bib96","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa2116154","article-title":"Vaccine efficacy in adults in a respiratory syncytial virus challenge study","volume":"386","author":"Schmoele-Thoma","year":"2022","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib97","doi-asserted-by":"publisher","first-page":"e637","DOI":"10.1093\/infdis\/jiae035","article-title":"Safety, tolerability and immunogenicity of a mRNA-based RSV vaccine in healthy young adults in a phase 1 clinical trial","volume":"230","author":"Shaw","year":"2024","journal-title":"J Infect Dis"},{"key":"2025070306220370900_bib98","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"2025070306220370900_bib99","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F protein-based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Sim\u00f5es","year":"2022","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib100","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"2025070306220370900_bib101","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.abj5508","article-title":"4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication","volume":"375","author":"Sourimant","year":"2022","journal-title":"Science"},{"key":"2025070306220370900_bib102","doi-asserted-by":"publisher","first-page":"eabo2236","DOI":"10.1126\/sciadv.abo2236","article-title":"Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase","volume":"8","author":"Sourimant","year":"2022","journal-title":"Sci Adv"},{"key":"2025070306220370900_bib103","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","article-title":"Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis","volume":"39","author":"Tejada","year":"2022","journal-title":"Adv Ther"},{"key":"2025070306220370900_bib104","doi-asserted-by":"publisher","first-page":"e747","DOI":"10.1016\/S1473-3099(24)00455-9","article-title":"The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access","volume":"24","author":"Terstappen","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib105","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/cid\/ciae085","article-title":"Seasonality, clinical characteristics, and outcomes of respiratory syncytial virus disease by subtype among children aged &lt;5 years: new Vaccine Surveillance Network, United States, 2016-2020","volume":"78","author":"Toepfer","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025070306220370900_bib106","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nm0109-21","article-title":"Fixing a failed vaccine","volume":"15","author":"Varga","year":"2009","journal-title":"Nat Med"},{"key":"2025070306220370900_bib107","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib108","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0140-6736(24)00138-7","article-title":"Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data","volume":"403","author":"Wang","year":"2024","journal-title":"Lancet"},{"key":"2025070306220370900_bib109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025070306220370900_bib110","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S1473-3099(23)00062-2","article-title":"Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data","volume":"23","author":"Wilkins","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025070306220370900_bib111","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib112","doi-asserted-by":"publisher","first-page":"e2416852","DOI":"10.1001\/jamanetworkopen.2024.16852","article-title":"Pediatric respiratory syncytial virus hospitalizations and respiratory support after the COVID-19 pandemic","volume":"7","author":"Winthrop","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025070306220370900_bib113","doi-asserted-by":"publisher","first-page":"R307","DOI":"10.1016\/j.cub.2022.02.057","article-title":"Natural infection of pangolins with human respiratory syncytial viruses","volume":"32","author":"Ye","year":"2022","journal-title":"Curr Biol"},{"key":"2025070306220370900_bib114","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S2213-2600(24)00246-7","article-title":"Early-life respiratory syncytial virus disease and long-term respiratory health","volume":"12","author":"Zar","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025070306220370900_bib115","doi-asserted-by":"publisher","first-page":"e1316","DOI":"10.1016\/S2214-109X(20)30251-5","article-title":"Early-life respiratory syncytial virus lower respiratory tract infection in a South African birth cohort: epidemiology and effect on lung health","volume":"8","author":"Zar","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2025070306220370900_bib116","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2313551","article-title":"Ziresovir in hospitalized infants with respiratory syncytial virus infection","volume":"391","author":"Zhao","year":"2024","journal-title":"N Engl J Med"},{"key":"2025070306220370900_bib117","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J Med Chem"},{"key":"2025070306220370900_bib118","doi-asserted-by":"publisher","first-page":"eabd6421","DOI":"10.1126\/sciadv.abd6421","article-title":"Community factors associated with local epidemic timing of respiratory syncytial virus: a spatiotemporal modeling study","volume":"7","author":"Zheng","year":"2021","journal-title":"Sci Adv"},{"key":"2025070306220370900_bib119","doi-asserted-by":"publisher","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"}],"container-title":["microLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/microlife\/advance-article-pdf\/doi\/10.1093\/femsml\/uqaf003\/61821901\/uqaf003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/microlife\/article-pdf\/doi\/10.1093\/femsml\/uqaf003\/61821901\/uqaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/microlife\/article-pdf\/doi\/10.1093\/femsml\/uqaf003\/61821901\/uqaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:22:25Z","timestamp":1751523745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/microlife\/article\/doi\/10.1093\/femsml\/uqaf003\/8006697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":117,"URL":"https:\/\/doi.org\/10.1093\/femsml\/uqaf003","relation":{},"ISSN":["2633-6693"],"issn-type":[{"value":"2633-6693","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"uqaf003"}}